A comparison of noninvasive tests
A systematic review and diagnostic test meta-analysis has found that the FibroScan-aspartate aminotransferase score, known as FAST, showed the highest sensitivity among evaluated imaging-based approaches for ruling out at-risk metabolic dysfunction-associated steatohepatitis, or MASH.
The analysis, published in the October issue of the American Journal of Gastroenterology, reviewed 20 eligible studies involving 9,480 participants. Researchers led by Shyna Zhuoying Gunalan of the National University of Singapore assessed how well several imaging-based technologies could identify or exclude at-risk MASH.
MASH is the inflammatory form of metabolic dysfunction-associated steatotic liver disease. Identifying patients considered at risk is clinically important because the condition can be associated with progressive liver damage. The study focused on whether noninvasive imaging-derived measures could help distinguish patients who should be ruled out from those whose results might support a rule-in assessment.
FAST led on sensitivity for ruling out disease
FAST recorded rule-out sensitivity of 0.871 in the meta-analysis, the highest reported among the evaluated approaches. Its specificity for the same rule-out use was 0.567. In practical terms, high sensitivity makes a test more useful for reducing the chance that a person with the target condition is missed when the test is used to exclude it.
The score combines measurements from FibroScan with aspartate aminotransferase, a blood enzyme marker. The authors said the result makes FAST a potentially practical option for wider implementation because of its accessibility and relatively lower cost compared with some other diagnostic methods.
Its performance was more mixed when used to rule in at-risk MASH. For that purpose, FAST had specificity of 0.900 but sensitivity of 0.441. That pattern suggests a positive result may be more useful for supporting concern in selected contexts than for finding every possible case, while its rule-out strength lies in its sensitivity.
MRI-based approaches also showed promise
The review did not identify a single universal winner across every diagnostic use. Magnetic resonance elastography combined with fibrosis-4 achieved high rule-out sensitivity of 0.812, with specificity of 0.606. For rule-in use, that combination had specificity of 0.872 and sensitivity of 0.500.
Other techniques produced intermediate or variable results. MRI-aspartate aminotransferase showed intermediate performance, according to the researchers. Iron-corrected T1 mapping thresholds showed variable diagnostic accuracy, indicating that performance may depend substantially on the threshold selected or the underlying study conditions.
Magnetic resonance-based technologies therefore remain well supported options for identifying at-risk MASH, the authors wrote. Their potential strength is tempered by the practical realities of access and cost, particularly when compared with approaches built around FibroScan and standard laboratory data.
Why the comparison matters
The central question is not simply which tool has the highest number on a single measure. Rule-out and rule-in applications place different demands on a test. A rule-out strategy generally values sensitivity, while a rule-in strategy places more weight on specificity. The study evaluated both uses, making it possible to compare technologies according to the clinical task they are intended to support.
In a sensitivity analysis limited to head-to-head studies, FAST again showed superior performance compared with the other diagnostic methods assessed. That consistency strengthened the authors’ conclusion that FAST may be especially useful where a scalable, noninvasive rule-out method is needed.
The findings do not eliminate the role of more advanced MRI-based testing. Instead, they point toward a possible division of labor: a more accessible test such as FAST may help with broad screening or exclusion, while magnetic resonance technologies can provide strong evidence in settings where they are available and appropriate.
Evidence, not a replacement for clinical judgment
The work is a meta-analysis, meaning its conclusions are drawn from the combined results of prior studies rather than from a new single-patient trial. It offers a broad view of diagnostic performance across the available evidence, but the reported values should be interpreted in the context of how individual tests are deployed, the patient populations studied, and the clinical thresholds in use.
The authors concluded that FAST may be the most practical choice for wide-scale implementation, while magnetic resonance-based technologies offer strong evidence for identifying at-risk MASH. Several authors disclosed ties to the biopharmaceutical industry.
For health systems and clinicians considering noninvasive pathways, the study provides a clearer comparative signal: FAST stood out for sensitivity when the goal is to rule out at-risk MASH, while MRI-based strategies remain important tools with distinct diagnostic tradeoffs.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
